CURRICULUM VITAE 2012, March



Similar documents
Noam Danenberg CEO N. Danenberg Holding Ltd

National Institute of Health Administration of Morocco

CURRICULUM VITAE PERSONAL INFORMATION. Lindell A. Busciglio, M.D North Habana Avenue Tampa, Florida (813)

Governing Health Systems in Africa

Rapid Assessment of Sexual and Reproductive Health

Up to $402,000. Insight HIV. Drug Class. 1.2 million people in the United States were living with HIV at the end of 2011 (most recent data).

Professor Matthew Weait Birkbeck, University of London

The Basics of Drug Resistance:

Theonest Ndyetabura KILIMANJARO CHRISTIAN MEDICAL CENTRE / KILIMANJARO CLINICAL RESERCH

Le métier d'infectiologue en Europe. Bruno Hoen Université de Franche Comté CHU de Besançon EGI 14 janvier 2011

Chairperson of the NEPAD Heads of State and Government Orientation Committee, President Macky Sall of the Republic of Senegal

Hepatitis C Treatment of Active IV Drug Users Tania Dunn, RN Isabelle Gendron, RN B.Sc.

Population Pharmacokinetics of Atazanavir in Naïve HIV Infected Patients using Medication Events Monitoring System (MEMS) for drug intake timing

Viral load testing. medical monitoring: viral load testing: 1

HIV Guidelines. New Strategies.

ACCESS TO AFFORDABLE TREATMENT FOR HIV/AIDS: THE ISSUES

Core Competencies: HIV/AIDS: HIV Basics HIV/AIDS JEOPARDY* Overview. To change category names: Instructions. 2. Introduce session.

Global Update on HIV Treatment 2013: Results, Impact and Opportunities

hiv/aids Programme Use of Antiretroviral Drugs for Treating Pregnant Women and Preventing HIV Infection in Infants

Synthesis of ECT evidence

Frequently Asked Questions (FAQs)

HIV New Diagnoses, Treatment and Care in the UK 2015 report

HIV/AIDS Prevention and Care

FEDERAL BUREAU OF PRISONS REPORT ON INFECTIOUS DISEASE MANAGEMENT

Aids Fonds funding for programmes to prevent HIV drug resistance

EYE DISEASES IN HIV-INFECTED INDIVIDUALS IN RURAL SOUTH AFRICA

Session 4: The Drug Management Cycle: Selection. David Peters

HIV/AIDS Care: The Diagnosis Code Series 2. Prepared By: Stacey L. Murphy, MPA, RHIA, CPC AHIMA Approved ICD-10-CM/ICD-10-CM Trainer

How To Teach In Marocco

In Tanzania, ARVs were introduced free-of-charge by the government in 2004 and, by July 2008, almost 170,000 people were receiving the drugs.

Incidencia y Características Clínicas del Síndrome Inflamatorio de Reconstitución Inmune (IRIS) en el Contexto de la Coinfección VIH-TB

Expérience appui ANR Zimbabwe (Medicines Control Authority of Zimbabwe -MCAZ) Corinne Pouget -AEDES

The Value of Innovation in HIV/AIDS Therapy

HIV DRUG RESISTANCE EARLY WARNING INDICATORS

Stigma and Discrimination

NATIONAL UNIVERSITY OF RWANDA HIV/AIDS CONTROL POLICY

Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents

EXPANDED HIV TESTING AND LINKAGE TO CARE (X-TLC) IN HEALTHCARE SETTINGS ON THE SOUTH SIDE OF CHICAGO

VICTOR NABHAN. Short CV. Victor Nabhan holds LLM law degrees from the University of Lyon, University of Paris, and New York University Law Schools.

Routine HIV Monitoring

Case Finding for Hepatitis B and Hepatitis C

Bloodborne Pathogens (HIV, HBV, and HCV) Exposure Management

International Symposium "Water, Recycling and Waste Valorisation ", ERVD 3 Conference center FMP-Fez, Morocco, 28 and 29 October 2015.

Presented By: Amy Medley PhD, MPH Centers for Disease Control and Prevention

Telephone:

Module 7: The Role of the Nurse

Comparative Drug Ranking for Clinical Decision Support in HIV Treatment

L hépatite virale C en Médecine Familiale- Rurale Montréal-Québec Mai 2015

CURRICULUM VITAE. Mohamed Ali BCHIR PERSONNAL INFORMATIONS

GARPR Online Reporting Tool

HIV (Human Immunodeficiency Virus) Screening and Pre-Exposure Prophylaxis Guideline

CURRICULUM VITAE PERSONAL INFORMATION. Scott S. Ubillos, M.D.

Estelle BROSSET Senior lecturer with habilitation to supervise doctoral theses Jean Monnet Chair Section 02- Public law

Under the title: Quality in Higher Education, for meet the needs of Enterprise and the Moroccan Society: Approaches, Practices and Evaluation Systems

João Silva de Mendonça, MD, PhD Infectious Diseases Service Hospital do Servidor Público Estadual São Paulo - Brazil

Table 5: HIV/AIDS statistics for Africa (excluding North Africa), 2001 and 2009

Co-infected health-care workers

UNAIDS 2014 LESOTHO HIV EPIDEMIC PROFILE

HIV Drug resistanceimplications

Tuberculosis and HIV/AIDS Co-Infection: Epidemiology and Public Health Challenges

Chapter 36. Media Directory. Characteristics of Viruses. Primitive Structure of Viruses. Therapy for Viral Infections. Drugs for Viral Infections

The Prize Fund for HIV/AIDS

New Approaches to a Major Public-Health Problem Infectious Diseases. Ethan Weiner, M.D. Senior Vice President Therapeutic Area Development Head

2 RENSEIGNEMENTS CONCERNANT L ASSURÉ SI CELUI-CI N EST PAS LE REQUÉRANT INFORMATION CONCERNING THE INSURED PERSON IF OTHER THAN THE APPLICANT

Please describe the laboratory facilities available in your research institute, including the items listed below (if applicable):

Journal of Infectious Diseases Advance Access published January 26, 2015

Ministère des Affaires Sociales et de la Santé, France

How To Get Rid Of Hiv

Georges Corm Economic & Financial Consultancy Office

ACCESS TO THE SEASONAL FLU VACCINE IN CANADA. How the flu shot makes its way from the laboratory to the doctor s office.

UNAIDS 2013 AIDS by the numbers

Borderless Diseases By Sunny Thai

1 Announcement Call for papers

Big data size isn t enough! Irene Petersen, PhD Primary Care & Population Health

«I-Reivac» Un réseau d excellence pour la recherche clinique en vaccinologie

Correlates of not receiving HIV care among HIV-infected women enrolling in a HRSA SPNS multi-site initiative

INTEGRATED CLINICAL SYSTEMS MANAGEMENT QUALITY IMPROVEMENT OF CARE OF PLWHA

The Medicines Patent Pool Understanding the Patent Status of Antiretroviral Drugs. Ellen t Hoen Medicines Patent Pool

Sofiane GHALI. Since 2010 : Dean, Higher School of Economic and Commercial Sciences of Tunis (E.S.S.E.C) University of Tunis.

The Botswana Combination Prevention Project (BCPP)

Technical guidance note for Global Fund HIV proposals in Round 11

HIV Continuum of Care Monitoring Framework 2014

Patent Expiry Impact Predictor

«Pourquoi la médecine palliative devrait(devra)-elle être une spécialité?» «Rencontre avec les experts européens» LYON le 10 Avril 2015

Transcription:

CURRICULUM VITAE 2012, March OVERVIEW INFORMATION Name: MARHOUM EL FILALI Kamal Date and birthplace: July 16, 1958 in Casablanca, Sex: Male Nationality: Moroccan Contact Information: Business contact Personal details Address: Faculté de Médecine Address: Résidence Mawlid 3, Appt C54 19, Rue Tarik Bnou Ziad Rue Abou Taour 20340 Casablanca, 20370 Casablanca, Tel: +212 5 22 48 20 66 Tel: +212 6 64 00 31 75 Fax: +212 5 22 20 43 33 Email: mefkamal@gmail.com Email: mefkamal@hotmail.com Areas of expertise: - Clinical experience in infectious diseases, particularly in care of HIV infected patients - Quantification of antiretroviral drugs needs for HIV infected patients in - HIV/AIDS prevention campaigns - Evaluation of projects related to HIV/AIDS - Education and training in the field of infectious diseases and HIV infection Expertise related to HIV/AIDS - In : Collaboration with the National AIDS Program Commitment in the Moroccan experience of access to care and to antiretroviral therapy Involvement in many national campaigns of prevention In charge of HIV infection course in the Faculty of Medicine and Pharmacy of Casablanca - At the international level : Collaboration as consultant with UNAIDS (Republic of Congo in 2001) Contribution to the development of an african consensus on antiretroviral therapy ( Dakar, October 2000 ) Collaboration as consultant with WHO-EMRO (Republic of Yemen in 2007) Collaboration as consultant with WHO-EMRO (Republic of Syria in 2009) Currently preparing a basic training on HIV infection in collaboration with WHO-EMRO

EDUCATION 1993 Certificate in Infected Patient Resuscitation Xavier Bichat University Paris, France 1993 Certificate in AIDS and retroviral diseases Xavier Bichat University, Paris, France 1993 Certificate Résident Etranger du Collège de Médecine des Hôpitaux de Paris 1989 Maghreban Certificate in Health Sciences Pedagogy Collège de Médecine des Hôpitaux de Paris, France Medical School, Casablanca, 1985 MD Medical School, Casablanca, 1976 1985 Medical School, Casablanca, 1976 Baccalaureate University of Bordeaux, France 1961 1976 Lycée Lyautey, Casablanca, TRAINING 2010, October Antifungal preceptorship meeting. University of South Manchester, UK 2008, February Human Participants Protection Education for Research Teams NIH, online course 2007, June Advanced Course on Security WHO, online course 2006, October GCP Training for investigators Roche, Casablanca, 2006, April Course on applied regression modelling University of Bristol and University of Bern, Cape Town, South Africa 2005, July Course : Managing Procurement and Logistics of HIV/AIDS Drugs and Related Supplies World Bank Institute, Beirut, Lebanon 2002, July Training : Clinical studies monitoring Georges Pompidou European Hospital, Paris, France 2001, March Atelier de mise à niveau des consultants francophones UNAIDS / WHO, Rabat, 2000, June The 2 nd african workshop on antiretrovirals Dakar, Senegal 1999, July The first African Workshop on Antiretrovirals Dakar, Senegal

1997, May Symposium on HIV infection Mediterranean Society of Infectious and Parasitic Diseases, Cairo, Egypt 1996, March Course on Research Methodology Medical School, Casablanca, 1995, April Course on biostatistics Medical School, Casablanca, 1992 1993 Training : Intensive care Bichat-Claude Bernard Hospital, Paris, France 1992, June Training : Digestive endoscopia Beaujon Hospital, Paris, France 1990, January Training : HIV infection care practice Bichat-Claude Bernard Hospital Paris, France WORKING EXPERIENCES Permanent positions Since 2011 Since 2003 Since 1997 Since 1997 Since 1988 Since 1987 Head of the Infectious Diseases Unit of Ibn Rochd University Hospital. Member of the National Committee of Management of HIV infection () Responsibility of ARVs quantification for the treatment of HIV infected patients in In charge of HIV infection course in the Medical School of Casablanca National Board member of Association de Lutte Contre le Sida Physician in charge of management of HIV infection in the Infectious Diseases Unit of Ibn Rochd University Hospital Academic positions (Medical School of Casablanca) 1993 Professor of Infectious Diseases 1989 1993 Associate Professor 1986 1989 Assistant 1984 1986 Resident 1976 1984 Medical student training

INVOLVEMENT IN RESEARCH GRANTS 2002 2009 : Evaluation of Subcutaneous Proleukin in a Randomized International Trial (ESPRIT001), a randomized, open label, phase III, international study of subcutaneous recombinant interleukin-2 (Proleukin ) in patients with HIV-1 infection and CD4 + Cell Counts 300/mm 3. Site principal investigator: Hakima Himmich The site of the Infectious Diseases Unit of Ibn Rochd University Hospital has enrolled 26 participants. Role in this research: Site co- investigator. Amount of money in the research grant: 103 664 GBP 2007 2011 : Study of Aldesleukin with and without Antiretroviral Therapy (STALWART : ESPRIT002), a randomized, open-label, international study of subcutaneous recombinant interleukin-2 (Aldesleukin ) with and without concomitant antiretroviral therapy in patients with HIV-1 infection and CD4 + Cell Counts 300/mm 3. Site principal investigator: Hakima Himmich The site of the Infectious Diseases Unit of Ibn Rochd University Hospital has enrolled 1 patient. Role in this research: Site co- investigator. Amount of money in the research grant: 3 162 GBP 2004 2007 : The SMART Study, a large, simple trial comparing the long-term clinical consequences of two Strategies for Management of Anti-Retroviral Therapy (Protocol CPCRA 065), the drug conservation strategy, a strategy aimed at conserving drugs through episodic use of antiretroviral treatment for the minimum time to maintain CD4+ cell count > 250 cells/mm3 versus the viral suppression strategy, a strategy aimed at suppressing viral load as much as possible, immediately following randomization and throughout follow up, irrespective of CD4+ cell count. Site principal investigator: Hakima Himmich The site of the Infectious Diseases Unit of Ibn Rochd University Hospital has enrolled 42 patients. Role in this research: Site investigator. Amount of money in the research grant: 307 382 USD 2010 - ongoing : Strategic Timing of AntiRetroviral Treatment (START), a randomized study to determine whether immediate initiation of antiretroviral treatment (ART) is superior to deferral of ART until the CD4+ declines below 350 cells/mm 3 in terms of morbidity and mortality in HIV-1 infected persons who are antiretroviral naïve with a CD4+ count above 500 cells/mm 3. The site of the Infectious Diseases Unit of Ibn Rochd University Hospital has included 21 patients and the enrolment is ongoing. Role in this research: site principal investigator. Amount of money in the research grant: 775 600 USD (if the goal of 50 patients is reached) 2003-2007 : The Antiretroviral Treatment in Lower Income Countries (ART-LINC) Collaboration to define prognosis of HIV-infected patients treated with HAART in resourcepoor settings, to compare experiences between different settings, delivery modes, and types of monitoring and to compare prognosis in resource-limited settings with that observed in industrialized nations. Principal investigators: François Dabis, Mathias Egger, Mauro Schechter The site of the Infectious Diseases Unit of Ibn Rochd University Hospital has participated with its cohort data. Role in this research: clinic representative. Research conducted by the University of Bern and the University of Bordeaux. Financial support of ANRS (France), CIHR (Canada) and NIH. Amount of money in the research grant: 14 180 USD

CONSULTATIONS AND PROGRAMMATIC EXPERIENCE 2011 Consultation on provider initiated HIV testing in health care settings 2010 Consultation on HIV prophylaxis in case of sexual violence 2006 Consultation on sharp waste management in hospital (2 nd phase) 2004 Consultation on sharp waste management in hospital 2003 Assessment and strengthening of referral centers for HIV infection management 2001 Consultation on implementation of Access Initiative Republic of Congo UNAIDS Since 2000 Coordinator of the education program for patients under ART 2000 Contribution to the development of an African consensus on ART Casablanca Dakar, Senegal Infectious diseases unit/gsk foundation Since 1997 Consultation on ARVs procurement and supplying Since 1993 Collaboration with the National AIDS Program REGIONAL EXPERIENCE March 2009 July 2007 Syria : Consultation for the development of the GFATM proposal (WHO). Yemen : Consultation on ART for the NAP at ART sites of Sanaa and Aden (WHO). 2002 2007 Member of the steering group of Antiretroviral Therapy in Low Income Countries (ART- LINC) collaboration Since 1994 July 2001 (Casablanca) : HIV Infection management Republic of Congo : Program Access of UNAIDS 1992 1993 France (Paris) : HIV infection management 1986 1991 (Casablanca) : Infectious diseases management 1984 1986 (Casablanca) : Internal medicine diseases management.

PUBLICATIONS 1. Sodqi M, Marih L, Oulad Lahsen A, Bensghir R, Chakib A, Himmich H, Marhoum El Filali K. Causes de décès de 91 patients ayant une infection à VIH traités par des antirétroviraux. La Presse Médicale 2012, in press 2. Fane M, Oulad Lahsen A, Bakhatar A, Sodqi M, Marhoum El Filali K, Bahlaoui A, Chakib A. Aspergilose pulmonaire et infection à VIH (à propos de deux cas). Rev Pneumol Clin 2012, 68, 1 :36-9 3. Oulad Lahsen A, Rachidi T, Sodqi M, Abada R, Marhoum El Filali K. Paralysie faciale associée à la leptospirose. Médecine et Maladies Infectieuses 2010; 40, 12 :716-717 4. Bakhouch K, Oulad-Lahcen A, Bensghir R, Blaghen M, Marhoum El Filali K, Ezzikouri S, Abidi O, Hassar M, Wakrim L. The prevalence of resistance-associated mutations to protease and reverse transcriptase inhibitors in treatment-naïve HIV1-infected individuals in Casablanca,. J Infect Dev Ctries 2009; 3(5):380-391 5. Kamal Marhoum El Filali, Hakima Himmich, Bloodstream infections. In : a guide to infection control in hospital (fourth edition), R. Wenzel, G. Bearman, T. Brewer, J.P. Butzler (Eds). Brookline, 2008 ; 170-72. 6. Sandrine Loubière, Kamal Marhoum El Filali, Mustapha Sodqi, Anderson Loundou, Stéphane Luchini, Susan Cleary, Jean-Paul Moatti, Hakima Himmich. When to initiate highly active antiretroviral therapy in low resource settings : the Moroccan experience. Antiviral Therapy 2008 ; 13 : 241-51 7. Gaëlle Krikorian, Kamal Marhoum El Filali, Hakima Himmich. L accès aux médicaments sous le nouveau régime de protection des brevets : cas du sida au Maroc. Knowledge Ecology Studies 2008 ; Vol.2 (Journal on-line : http://www.kestudies.org/) 8. ART-LINC Collaboration. Antiretroviral Therapy in Lower Income Countries (ART-LINC): International collaboration of treatment cohorts. Int J Epidemiol. 2005 Oct;34(5):979-86 9. Marih L, Sodqi M, Chakib A, Malmoussi M, Ouagari Z, Marhoum El Filali K, Himmich H. Kaposi cutané de forme tumorale: difficultés diagnostiques à propos d un cas. Rev Maroc Med Santé 2005, 22, 1 : 44-47 10. Guide de la prise en charge de l infection à VIH. Edité par le Ministère de la Santé, avec le soutien de l OMS, sous la coordination du Pr Hakima Himmich, Rabat, 2004. 11. Malmoussi M, Zerouali K, Aajly L, Marhoum El Filali K, El Mdaghri N, Benbachir M, Himmich H. Méningite à méningocoque de l adulte à propos de 117 cas. J Magh A Réa 2003, 43 : 262-5 12. Marih l, Sodqi M, Bensghir R, Marhoum El Filali K, Himmich H. Monitoring for efficacy of HAART in limited resource countries. Proceeding of International AIDS Conference, July 2002. 363-364. 13. Sodqi M, Marih L, Marhoum El Filali K, Himmich H. Infection with Mycobacterium tuberculosis among HIV infected patients in. Proceedings of the XIV International AIDS Conference. July 2002. Barcelone. 14. Soussi-Abdallaoui M, El Kadioui-El Idrissi F, Chakib A, Marhoum El Filali K, Himmich H, Guessous-Idrissi N. Isospora belli au Maroc à propos de 4 nouveaux cas. Les Cahiers du Medecin 2002, 48 : 41-43. 15. Marhoum El Filali K, A Chakib, Himmich H. Accès aux antirétroviraux au Maroc. Bulletin S.M.S.M 1999, 1 : 17 21. 16. Marhoum El Filali K. Prise en charge d un malade infecté par le VIH. Les cahiers du Médecin 1998 ; 11 : 25 27 17. Marhoum El Filali K. Prophylaxie de l infection à VIH après une exposition accidentelle au sang. Les cahiers du Médecin 1998 ; 11 : 28 29 18. Zahraoui M, Arssi M, Marhoum El Filali K, Chakib A, Himmich H. Tuberculose et infection par le VIH. Rev Maroc Med Santé 1992, 14,1 : 7-12